Geoffrey Liu focuses on Internal medicine, Lung cancer, Cancer, Oncology and Odds ratio. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Allele and Pathology. Geoffrey Liu combines subjects such as Respiratory disease, Surgery, Immunology, Carcinoma and Genotype with his study of Lung cancer.
His Immunology research incorporates elements of Body mass index, Haplotype and Hazard ratio. His biological study spans a wide range of topics, including DNA Mutational Analysis, Plasma cell, Cancer research, DNA methylation and Family history. Geoffrey Liu interconnects Geriatric assessment, Allele frequency, Epidermal growth factor receptor and Risk factor in the investigation of issues within Oncology.
Internal medicine, Oncology, Lung cancer, Cancer and Odds ratio are his primary areas of study. His Internal medicine research includes elements of Gastroenterology and Genotype. His Oncology study incorporates themes from Single-nucleotide polymorphism, Proportional hazards model and Bioinformatics.
The study incorporates disciplines such as Respiratory disease, Cancer research, Surgery, Immunology and Carcinoma in addition to Lung cancer. Geoffrey Liu has included themes like Logistic regression, Smoking cessation, Family medicine, Disease and Physical therapy in his Cancer study. His Odds ratio research includes themes of Case-control study and Allele.
His primary areas of investigation include Internal medicine, Oncology, Lung cancer, Cancer and Cancer research. His Internal medicine study combines topics in areas such as Mendelian randomization and Genome-wide association study. His Oncology study also includes fields such as
In Lung cancer, Geoffrey Liu works on issues like Adenocarcinoma, which are connected to Lung. His Cancer research is multidisciplinary, relying on both Alcohol consumption, Logistic regression, Smoking cessation and Patient education. His Cancer research study combines topics in areas such as Cell culture and Drug resistance.
His primary areas of study are Internal medicine, Lung cancer, Oncology, Hazard ratio and Cancer research. His Internal medicine research focuses on Single-nucleotide polymorphism and how it relates to Mendelian randomization. His work carried out in the field of Lung cancer brings together such families of science as Body mass index, Allele, Lung cancer susceptibility, Cohort and Adenocarcinoma.
His Oncology research is multidisciplinary, relying on both Cancer, Obesity, Incidence, Confidence interval and Risk factor. The study incorporates disciplines such as Overweight, Underweight, Antibody and Proportional hazards model in addition to Hazard ratio. His Cancer research research is multidisciplinary, incorporating elements of Anaplastic lymphoma kinase, Crizotinib, Alectinib, Carcinoma and microRNA.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw;Dong Wan Kim;Ranee Mehra;Daniel S W Tan.
The New England Journal of Medicine (2014)
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25
Rayjean J. Hung;James D. Mckay;Valerie Gaborieau;Paolo Boffetta.
Patient preferences for oral versus intravenous palliative chemotherapy.
G Liu;E Franssen;M I Fitch;E Warner.
Journal of Clinical Oncology (1997)
Probability of Cancer in Pulmonary Nodules Detected on First Screening CT
Annette McWilliams;Martin C. Tammemagi;John R. Mayo;Heidi Roberts.
The New England Journal of Medicine (2013)
Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study
Robert Carreras-Torres;Mattias Johansson;Philip C. Haycock;Kaitlin H. Wade.
PLOS ONE (2017)
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Alice T Shaw;Tae Min Kim;Lucio Crinò;Cesare Gridelli.
Lancet Oncology (2017)
Sensitive tumour detection and classification using plasma cell-free DNA methylomes
Shu Yi Shen;Rajat Singhania;Gordon Fehringer;Ankur Chakravarthy.
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Dong Wan Kim;Ranee Mehra;Daniel S W Tan;Enriqueta Felip.
Lancet Oncology (2016)
XPD and XRCC1 Genetic Polymorphisms Are Prognostic Factors in Advanced Non—Small-Cell Lung Cancer Patients Treated With Platinum Chemotherapy
Sarada Gurubhagavatula;Geoffrey Liu;Sohee Park;Wei Zhou.
Journal of Clinical Oncology (2004)
Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
Wei Zhou;Sarada Gurubhagavatula;Geoffrey Liu;Sohee Park.
Clinical Cancer Research (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: